Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion type Assertion NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_head.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion description "[Chronic treatment with AVE3085 did not alter arterial BP or severe hyperglycaemia, but did lead to significantly increased production of eNOS (+95%), cGMP (+128%) and VASP phosphorylation (+65%) as well as to improved vascular function (+36%) associated with reduced production of ICAM-1 (-36%) and VCAM-1 (-58%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_provenance.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion evidence source_evidence_literature NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_provenance.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion SIO_000772 18825362 NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_provenance.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion wasDerivedFrom befree-20140225 NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_provenance.
- NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_assertion wasGeneratedBy ECO_0000203 NP242062.RAcI5LZcFDOv2v92b8ek7Bc4KDRUwm6Q-ZUj7_dVj-iXo130_provenance.